ASE · Financial Statements

Matinas Biopharma Holdings, Inc. (MTNB) Financial Statements

$1.70 ASE: MTNB Market Cap $726291

Matinas Biopharma Holdings, Inc. most recently reported annual revenue of $0, a net loss of $10.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Matinas Biopharma Holdings, Inc.: net profit was positive in 0 of 10 reported years; operating margin moved from -11024.6% to -2168.4%, a shift of +8856.2 percentage points; the most recent year shows a net loss of $10.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$0$3.0M$1.0M$0$0
Operating Expenses$8.0M$17.0M$15.0M$19.0M$24.0M$25.0M$28.0M$25.0M$20.0M$7.0M
Operating Profit$-8.0M$-17.0M$-15.0M$-19.0M$-24.0M$-25.0M$-25.0M$-24.0M$-20.0M$-7.0M
Operating Margin0.0%-11024.6%-12230.9%-21067.4%-15288.4%-74954.6%-771.3%-2168.4%0.0%0.0%
Other Income$1.0M$1.0M$0$2.0M$2.0M$1.0M$4.0M$1.0M$-4.0M$-3.0M
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$0$0$1.0M$1.0M$0
Profit Before Tax$-8.0M$-16.0M$-15.0M$-17.0M$-22.0M$-23.0M$-21.0M$-23.0M$-24.0M$-10.0M
Tax$0$2.3M$3.5M$0$0$0$0$0$330,000$0
Net Profit$-8.0M$-15.0M$-14.0M$-17.0M$-22.0M$-23.0M$-21.0M$-23.0M$-24.0M$-10.0M
EPS$-98.85$-128.40$-107.70$-80.55$-78.45$-75.60$-45.00$-79.20$-74.70$-30.00
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$6.0M$6.0M$6.0M$6.0M$4.0M$8.0M$2.0M$2.0M$2.0M$2.0M$2.0M$2.0M
Operating Profit$-6.0M$-6.0M$-6.0M$-6.0M$-4.0M$-8.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-6.0M$-5.0M$-6.0M$-6.0M$-4.0M$-9.0M$-2.0M$-5.0M$-2.0M$-2.0M$-2.0M$-1.0M
Tax$0$0$0$0$0$940,000$0$0$0$0$0$0
Net Profit$-6.0M$-5.0M$-6.0M$-6.0M$-4.0M$-8.0M$-2.0M$-5.0M$-2.0M$-2.0M$-2.0M$-1.0M
EPS$-1.39$-1.22$-1.34$-1.15$-0.85$-1.73$-0.33$-1.03$-0.40$-0.30$-0.30$-0.21

Over the 10 years reported for Matinas Biopharma Holdings, Inc., cash stood at $4.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.00 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$10.0M$14.0M$20.0M$40.0M$71.0M$61.0M$79.0M$25.0M$13.0M$7.0M
Current Assets$5.0M$8.0M$13.0M$30.0M$62.0M$51.0M$35.0M$16.0M$8.0M$4.0M
Cash$4.0M$7.0M$12.0M$22.0M$12.0M$21.0M$7.0M$5.0M$7.0M$4.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$0
Fixed Assets$0$2.0M$2.0M$6.0M$5.0M$6.0M$6.0M$5.0M$2.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$6.0M$46.0M$29.0M$22.0M$9.0M$0$0
Other Assets$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$0$0
Total Liabilities$3.0M$4.0M$4.0M$7.0M$7.0M$9.0M$42.0M$6.0M$5.0M$2.0M
Current Liabilities$1.0M$2.0M$3.0M$3.0M$4.0M$4.0M$4.0M$3.0M$3.0M$1.0M
Borrowings$0$0$0$4.0M$4.0M$5.0M$4.0M$4.0M$3.0M$1.0M
Other Liabilities$3.0M$3.0M$3.0M$3.0M$3.0M$4.0M$38.0M$2.0M$2.0M$1.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$7.0M$11.0M$16.0M$33.0M$64.0M$52.0M$37.0M$19.0M$8.0M$5.0M

For Matinas Biopharma Holdings, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $7.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-6.0M$-11.0M$-10.0M$-14.0M$-17.0M$-15.0M$-19.0M$-15.0M$-16.0M$-7.0M
Investing Cash Flow$0$-944.0M$-537.0M$-12.0M$-41.0M$17.0M$4.0M$13.0M$9.0M$0
Financing Cash Flow$4.4B$623.0M$603.0M$2.3B$684.0M$1.0M$0$0$0$0
Net Cash Flow$1.0M$3.0M$5.0M$10.0M$-10.0M$9.0M$-14.0M$-2.0M$2.0M$-3.0M
Free Cash Flow$-6.0M$-12.0M$-11.0M$-14.0M$-17.0M$-15.0M$-20.0M$-15.0M$-16.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.06
FCF Yield-569.41%
Quick Ratio0.85
Interest Coverage—
Return 1Y-65.59%
Return 3Y-98.13%
Return 5Y-99.05%

Matinas Biopharma Holdings, Inc. (MTNB) financials — frequently asked questions

What is Matinas Biopharma Holdings, Inc.'s annual revenue?

Matinas Biopharma Holdings, Inc. (MTNB) reported annual revenue of $0 in its most recent fiscal year.

What is Matinas Biopharma Holdings, Inc.'s net profit?

Matinas Biopharma Holdings, Inc. (MTNB) reported a net loss of $10.0M in its most recent fiscal year.

What is MTNB EV/EBITDA?

Matinas Biopharma Holdings, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.06. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
MTNB Overview MTNB Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.